<DOC>
	<DOCNO>NCT01737398</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety IONIS-TTR Rx give 65 week patient Familial Amyloid Polyneuropathy</brief_summary>
	<brief_title>Efficacy Safety IONIS-TTR Rx Familial Amyloid Polyneuropathy</brief_title>
	<detailed_description>Familial Amyloid Polyneuropathy ( FAP ) rare , hereditary disease cause mutation transthyretin ( TTR ) protein . TTR make liver secrete blood . TTR mutation cause misfold deposit multiple organ cause FAP . IONIS-TTR Rx antisense drug design decrease amount mutant normal TTR make liver . It predict decrease amount TTR protein result decrease formation TTR deposit , thus slow stop disease progression . The purpose study determine IONIS-TTR Rx slow stop nerve damage cause TTR deposit . This study enroll late Stage 1 early Stage 2 FAP patient . Patients receive either IONIS-TTR Rx placebo 65 week .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Stage 1 Stage 2 FAP patient follow : 1 . NIS score within protocol criterion 2 . Documented transthyretin variant genotyping 3 . Documented amyloid deposit biopsy Females childbearing potential must use appropriate contraception must nonpregnant nonlactating . Males engage relation childbearing potential must use appropriate contraception Low Retinol level screen Karnofsky performance status ≤50 Poor Renal function Known type 1 type 2 diabetes mellitus Other cause sensorimotor autonomic neuropathy ( e.g. , autoimmune disease ) If previously treat Vyndaqel® , must discontinue treatment 2 week prior Study Day 1 . If previously treat Diflunisal , must discontinue treatment 3 day prior Study Day 1 Previous treatment oligonucleotide siRNA within 12 month screen Prior liver transplant anticipate liver transplant within 1 yr screen New York Heart Association ( NYHA ) functional classification ≥3 Acute Coronary Syndrome major surgery within 3 month screen Known Primary Leptomeningeal Amyloidosis Anticipated survival le 2 year Have condition opinion investigator could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>